/
PVLA
$156.55+$1.48 (+0.95%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$2.2B
14M shares
52-week range
$41.71 – $161.38
96% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change+$143.72
Palvella Therapeutics, Inc. Common Stock
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
www.palvellatx.com- Employees
- 29
- IPO / List date
- Dec 16, 2024
- HQ
- WAYNE, PA
Held by traders on TradeandTell
No one on the platform currently holds PVLA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 17,970 | $2.2M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded PVLA yet.
